Suppr超能文献

对全球常规免疫接种覆盖率的分析显示,在新冠疫情的头两年出现了中断和停滞,2022年出现初步复苏。

Analysis of global routine immunisation coverage shows disruption and stagnation during the first two-years of the COVID-19 pandemic with tentative recovery in 2022.

作者信息

Evans Beth, Keiser Olivia, Kaiser Laurent, Jombart Thibaut

机构信息

Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.

出版信息

Vaccine X. 2023 Sep 6;15:100383. doi: 10.1016/j.jvacx.2023.100383. eCollection 2023 Dec.

Abstract

Whilst it is now widely recognised that routine immunisation (RI) was disrupted by the COVID-19 pandemic in 2020, and further so in 2021, the extent of continued interruptions in 2022 and/or rebounds to previous trends remains unclear. We modelled country-specific RI trends using validated estimates of national coverage from the World Health Organisation and United Nation Children's Fund for 182 countries (accounting for > 97% of children globally), to project expected diphtheria, tetanus, and pertussis-containing vaccine first-dose (DTP1), third-dose (DTP3) and measles-containing vaccine first-dose (MCV1) coverage for 2020-2022 based on pre-pandemic trends (from 2000 to 2019). We provide further evidence of peak pandemic immunisation disruption in 2021, followed by tentative recovery in 2022. We report a 3.4% (95 %CI: [2.5%; 4.4%]) decline in global DTP3 coverage in 2021 compared to 2000-2019 trends, from an expected 89.8% to reported 86.4%. This coverage gap reduced to a 2.7% (95 %CI: [1.8%; 3.6%]) decline in 2022, with reported coverage rising to 87.2%. Similar results were seen for DTP1 and MCV1. Whilst partial rebounds are encouraging, global coverage decline translates to a 17-year setback in RI to 2005 levels, and the majority of countries retain coverage at or lower than pre-pandemic levels. The Americas, Africa, and Asia were the most impacted regions; and low- and middle-income countries the most affected income groups. The number of annual Zero Dose (ZD) children - indicating those receiving no immunisations - increased from 12.1 million (M) globally in 2019 to a peak of 16.7 M in 2021, then reduced to 13.1 M in 2022. Overall, we estimate an excess of 8.8 M ZD children cumulatively in 2020-2022 compared to pre-pandemic levels. This work can be used as an objective baseline to inform future interventions to prioritise and target interventions, and facilitate catch-up of growing populations of under- and un-immunised children.

摘要

虽然现在人们普遍认识到常规免疫接种(RI)在2020年受到了新冠疫情的干扰,2021年干扰进一步加剧,但2022年持续中断的程度和/或是否恢复到之前的趋势仍不清楚。我们利用世界卫生组织和联合国儿童基金会对182个国家(占全球儿童的97%以上)国家覆盖率的有效估计,对各国的RI趋势进行建模,以根据疫情前(2000年至2019年)的趋势预测2020 - 2022年白喉、破伤风和含百日咳疫苗首剂(DTP1)、第三剂(DTP3)以及含麻疹疫苗首剂(MCV1)的覆盖率。我们提供了进一步的证据,表明2021年疫情期间免疫接种中断达到峰值,随后在2022年出现初步恢复。我们报告称,与2000 - 2019年的趋势相比,2021年全球DTP3覆盖率下降了3.4%(95%置信区间:[2.5%;4.4%]),从预期的89.8%降至报告的86.4%。2022年,这一覆盖率差距缩小至下降2.7%(95%置信区间:[1.8%;3.6%]),报告的覆盖率升至87.2%。DTP1和MCV1也出现了类似结果。虽然部分恢复令人鼓舞,但全球覆盖率下降意味着RI倒退至2005年的水平,倒退了17年,而且大多数国家的覆盖率维持在疫情前水平或更低。美洲、非洲和亚洲是受影响最严重的地区;低收入和中等收入国家是受影响最严重的收入群体。年度零剂量(ZD)儿童数量——即未接受任何免疫接种的儿童——从2019年全球的1210万增加到2021年的峰值1670万,然后在2022年降至1310万。总体而言,我们估计2020 - 2022年累计有超过880万ZD儿童,比疫情前水平有所增加。这项工作可用作客观基线,为未来的干预措施提供信息,以便对干预措施进行优先排序和靶向定位,并促进对未接种和未充分接种疫苗的不断增长的儿童群体进行补种。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f141/10568411/b82784e9ed5d/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验